California State Teachers Retirement System Increases Stock Holdings in Illumina, Inc. $ILMN

California State Teachers Retirement System boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 16,869.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,144,099 shares of the life sciences company's stock after buying an additional 39,907,533 shares during the period. California State Teachers Retirement System owned approximately 26.59% of Illumina worth $7,058,537,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. Capital World Investors grew its stake in shares of Illumina by 0.6% during the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company's stock worth $2,636,483,000 after acquiring an additional 124,323 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Illumina in the 2nd quarter valued at approximately $3,374,423,000. State Street Corp boosted its stake in Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company's stock worth $811,895,000 after purchasing an additional 190,324 shares in the last quarter. WCM Investment Management LLC boosted its stake in Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company's stock worth $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Illumina news, Director Keith Meister sold 457,858 shares of the company's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares of the company's stock, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 2,062,465 shares of company stock worth $436,589,802 over the last three months. Company insiders own 2.90% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on ILMN shares. Zacks Research lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 1st. Daiwa Securities Group upgraded shares of Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 price objective for the company in a research note on Thursday, May 14th. Barclays boosted their price objective on shares of Illumina from $145.00 to $160.00 and gave the company an "underweight" rating in a report on Friday, July 31st. Sanford C. Bernstein reissued a "market perform" rating and issued a $215.00 target price on shares of Illumina in a research report on Friday, July 31st. Finally, JPMorgan Chase & Co. raised their target price on Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Illumina currently has an average rating of "Hold" and an average target price of $191.31.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: S&P 500 inclusion should support demand. Illumina will join the S&P 500 before the market opens on September 21, moving up from the S&P MidCap 400. The change is expected to generate buying from index-tracking funds and increase the company’s visibility among institutional investors. Illumina and Everpure to Join S&P 500 in September Rebalancing
• Positive Sentiment: Analyst sentiment has improved. Zacks upgraded Illumina to Rank #2, or “Buy,” citing greater optimism about its earnings outlook. The upgrade could provide additional short-term momentum. Illumina Upgraded to Buy
• Positive Sentiment: Business quality remains a bullish theme. Commentary highlights Illumina’s leadership in gene sequencing and the expanding use of genomics in diagnostics and precision medicine. Investors are weighing whether continued operational strength can justify the stock’s recent advance. ILMN Stock Keeps Climbing

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $211.06 on Wednesday. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $231.81. The company's 50 day moving average is $199.86 and its 200 day moving average is $160.68. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The company has a market cap of $31.87 billion, a PE ratio of 39.38, a price-to-earnings-growth ratio of 3.09 and a beta of 1.46.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business's quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.